Correction of Zinc Deficiency in Children With Chronic Kidney Disease and Kidney Transplant
Renal Insufficiency, Chronic, Zinc Deficiency, Trace Element Excess
About this trial
This is an interventional treatment trial for Renal Insufficiency, Chronic
Eligibility Criteria
Inclusion Criteria:
- Children between 4 and 18 years of age; diagnosis of CKD; renal transplant recipient with declining renal function (eGFR<90 ml/min/1.73 m2).
Exclusion Criteria:
- Children with CKD or kidney transplant younger than 4 years. Kidney transplant recipients with eGFR>90 ml/min/1.73 m2.
Sites / Locations
- McMaster Children's Hospital
- Children's Hospital, London Health Science Centre University of Western Ontario
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Zinc deficient patients
Zinc sufficient patients
If the patient is found to be zinc deficient (serum zinc < 11.5 μmol/L), the family will be contacted by the RA to commence zinc supplement: zinc citrate (Zinc Lozenges, manufactured by Douglas Laboratories Inc, London, ON, Health Canada NPN 80032476) for 3 months. As per the NPN licence the dose is 10 mg (1 lozenge) orally once a day for children age 4-8 years, and 10 mg twice a day for children age 9-18 years. This should give enough time to restore serum zinc to normal in most patients.
Zinc sufficient patients will repeat blood and urine tests in 3 month time to compare the changes with intervention arm.